Back to Search Start Over

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study

Authors :
Nienke Legdeur
Maryam Badissi
Stephen F. Carter
Sophie de Crom
Aleid van de Kreeke
Ralph Vreeswijk
Marijke C. Trappenburg
Mardien L. Oudega
Huiberdina L. Koek
Jos P. van Campen
Carolina J. P. W. Keijsers
Chinenye Amadi
Rainer Hinz
Mark F. Gordon
Gerald Novak
Jana Podhorna
Erik Serné
Frank Verbraak
Maqsood Yaqub
Arjan Hillebrand
Alessandra Griffa
Neil Pendleton
Sophia E. Kramer
Charlotte E. Teunissen
Adriaan Lammertsma
Frederik Barkhof
Bart N. M. van Berckel
Philip Scheltens
Majon Muller
Andrea B. Maier
Karl Herholz
Pieter Jelle Visser
Source :
BMC Geriatrics, Vol 18, Iss 1, Pp 1-16 (2018)
Publication Year :
2018
Publisher :
BMC, 2018.

Abstract

Abstract Background The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study. Methods The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer’s Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures. Discussion The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. Trial registration Nederlands Trial Register NTR5867. Registered 20 May 2016.

Details

Language :
English
ISSN :
14712318
Volume :
18
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Geriatrics
Publication Type :
Academic Journal
Accession number :
edsdoj.f13a64ec542e4e3495b4475727bca552
Document Type :
article
Full Text :
https://doi.org/10.1186/s12877-018-0984-z